サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1414367

マントル細胞リンパ腫治療薬の世界市場レポート 2024年

Mantle Cell Lymphoma Therapeutics Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 200 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
マントル細胞リンパ腫治療薬の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

マントル細胞リンパ腫治療薬市場規模は近年力強く成長しています。2023年の22億6,000万米ドルから2024年には24億5,000万米ドルへと、CAGR8.5％で拡大します。過去数年間に見られた拡大は、研究の進展、臨床試験の成功、診断ツールの強化、治療へのアクセスの拡大、共同研究イニシアティブによるものです。

マントル細胞リンパ腫の有病率の増加が予想されることから、マントル細胞リンパ腫治療薬市場の拡大が見込まれます。マントル細胞リンパ腫（MCL）は非ホジキンリンパ腫（NHL）の一種で、リンパ系に影響を及ぼします。マントル細胞リンパ腫の治療薬は、患者の転帰の改善、生存期間の延長、疾病負担の軽減につながる病態を治療・管理することにより、この疾患の蔓延を抑制する上で極めて重要な役割を果たしています。2022年12月現在、米国連邦政府が運営する米国の生物医学図書館である国立医学図書館は、マントル細胞リンパ腫の年間発生率を20万人当たり1例と報告しており、非ホジキンリンパ腫全体の5％に寄与しています。このように、マントル細胞リンパ腫の有病率の上昇は、マントル細胞リンパ腫治療薬市場の成長の起爆剤となっています。

遠隔医療サービスの利用可能性の増加がマントル細胞リンパ腫治療薬市場を押し上げようとしています。遠隔医療サービスは、通信技術を利用してヘルスケアサービスや医療相談を遠隔で提供するものです。遠隔医療サービスの急増は、マントル細胞リンパ腫治療薬市場におけるアクセシビリティ、効率性、患者エンゲージメントを向上させ、全体的なケアと治療成果の改善に寄与します。米国の政府機関である疾病予防管理センター（Centers for Disease Control and Prevention）の2022年10月の報告によると、成人の37.0％が2021年の過去12ヵ月間に遠隔医療サービスを利用したと報告しています。注目すべきは、男性（31.7％）に比べて女性の遠隔医療利用率が高いこと（42.0％）です。さらに、年齢と遠隔医療利用には正の相関関係が見られ、成人の遠隔医療利用率は18～29歳の29.4％から65歳以上の43.3％に上昇しました。その結果、遠隔医療サービスの成長がマントル細胞リンパ腫治療薬市場を促進しています。

2023年のマントル細胞リンパ腫治療薬世界市場で最大の地域は北米でした。マントル細胞リンパ腫治療薬市場レポートの対象地域は、アジア太平洋,西欧,東欧,北米,南米,中東,アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界のマントル細胞リンパ腫治療薬市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 併用療法
  • 単独療法
  • 世界のマントル細胞リンパ腫治療薬市場、作用機序別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • ブルトンチロシンキナーゼ阻害剤
  • アルキル化剤
  • デオキシリボ核酸合成阻害剤
  • 微小管阻害剤
  • モノクローナル抗体
  • その他の作用機序
  • 世界のマントル細胞リンパ腫治療薬市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 経口
  • 非経口
  • 世界のマントル細胞リンパ腫治療薬市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院
  • 研究
  • その他の用途

第7章 地域および国の分析

  • 世界のマントル細胞リンパ腫治療薬市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界のマントル細胞リンパ腫治療薬市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • マントル細胞リンパ腫治療薬市場の競合情勢
  • マントル細胞リンパ腫治療薬市場の企業プロファイル
    • AstraZeneca plc
    • Celgene Corporation
    • Johnson &Johnson Consumer Inc.
    • Takeda Pharmaceutical Company Limited
    • Bayer Aktiengesellschaft

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の見通しと可能性の分析

第35章 付録

目次
Product Code: r11877

“Mantle Cell Lymphoma Therapeutics Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on mantle cell lymphoma therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for mantle cell lymphoma therapeutics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The mantle cell lymphoma therapeutics market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Type: Combination Therapy; Monotherapy
  • 2) By Mechanism of Action: Bruton Tyrosine Kinase Inhibitors; Alkylating Agents; Deoxyribonucleic Acid Synthesis Inhibitors; Microtubule Inhibitors; Monoclonal Antibodies; Other Mechanisms
  • 3) By Route of Administration: Oral; Parenteral
  • 4) By Application: Hospital; Research Institute; Other Applications
  • Companies Mentioned: AstraZeneca plc; Celgene Corporation; Johnson & Johnson Consumer Inc.; Takeda Pharmaceutical Company Limited; Bayer Aktiengesellschaft
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Mantle cell lymphoma therapeutics pertains to the treatment approaches and strategies employed for the management of mantle cell lymphoma (MCL), a subtype of non-Hodgkin lymphoma characterized by abnormal B-cell growth in the lymphatic system. These treatments utilize targeted strategies, including BTK and BCL2 inhibitors, known for their enduring therapeutic effects.

The primary categories of mantle cell lymphoma therapeutics encompass combination therapy and monotherapy. Combination therapy involves the simultaneous utilization of multiple treatments or medications to enhance their effectiveness in addressing a specific condition or disease. In the context of mantle cell lymphoma therapeutics, combination therapy integrates various approaches such as chemotherapy, targeted therapy, and immunotherapy to optimize treatment outcomes and enhance patient well-being. The drugs function through Bruton tyrosine kinase inhibitors, alkylating agents, deoxyribonucleic acid synthesis inhibitors, microtubule inhibitors, monoclonal antibodies, among others, and can be administered through oral and parenteral routes. These therapeutic interventions find application in hospitals, research institutes, and other healthcare settings.

The mantle cell lymphoma therapeutics market research report is one of a series of new reports from The Business Research Company that provides mantle cell lymphoma therapeutics market statistics, including the mantle cell lymphoma therapeutics industry global market size, regional shares, competitors with a mantle cell lymphoma therapeutics market share, detailed mantle cell lymphoma therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the mantle cell lymphoma therapeutics industry. This mantle cell lymphoma therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The mantle cell lymphoma therapeutics market size has grown strongly in recent years. It will grow from $2.26 billion in 2023 to $2.45 billion in 2024 at a compound annual growth rate (CAGR) of 8.5%. The expansion observed in the historical period can be credited to progress in research, successful clinical trials, enhancements in diagnostic tools, the widening access to treatment, and collaborative research initiatives.

The mantle cell lymphoma therapeutics market size is expected to see strong growth in the next few years. It will grow to $3.29 billion in 2028 at a compound annual growth rate (CAGR) of 7.6%. The anticipated growth in the forecast period can be ascribed to advancements in targeted therapies, innovations in immunotherapy, trends in personalized medicine, the global expansion of the market, and the rising incidence rates. Key trends expected in the forecast period encompass advancements in immunotherapy, the development of precision medicine and biomarkers, targeted therapies addressing specific pathways, the utilization of combination therapies, and the integration of artificial intelligence (AI).

The anticipated increase in the prevalence of mantle cell lymphoma is set to drive the expansion of the mantle cell lymphoma therapeutics market. Mantle cell lymphoma (MCL) represents a form of non-Hodgkin lymphoma (NHL), impacting the lymphatic system. Therapeutics for mantle cell lymphoma play a pivotal role in curbing the prevalence of the disease by treating and managing the condition, leading to improved patient outcomes, prolonged survival, and diminished disease burden. As of December 2022, the National Library of Medicine, a US-based biomedical library operated by the United States Federal Government, reported an annual incidence of one case of mantle cell lymphoma per 200,000 people, contributing to 5% of all non-Hodgkin lymphomas. Thus, the escalating prevalence of mantle cell lymphoma is a catalyst for the growth of the mantle cell lymphoma therapeutics market.

The increasing availability of telemedicine services is poised to elevate the mantle cell lymphoma therapeutics market. Telemedicine services involve delivering healthcare services and medical consultations remotely, utilizing telecommunications technology. The surge in telemedicine services enhances accessibility, efficiency, and patient engagement within the mantle cell lymphoma therapeutics market, contributing to overall improved care and treatment outcomes. According to an October 2022 report from the Centers for Disease Control and Prevention, a US-based government agency, 37.0% of adults reported having utilized telemedicine services in the previous 12 months of 2021. Notably, women exhibited a higher likelihood of telemedicine usage (42.0%) compared to men (31.7%). Additionally, a positive correlation was observed between age and telemedicine usage, with the percentage of adults engaging in telemedicine rising from 29.4% among those aged 18-29 to 43.3% among adults aged 65 and above. Consequently, the growth of telemedicine services is propelling the mantle cell lymphoma therapeutics market.

A significant trend gaining traction in the mantle cell lymphoma therapeutics market is the development of targeted therapy drugs. Major players in the market are actively involved in creating new drugs for targeted therapy to maintain their market standing. For instance, in March 2023, AstraZeneca plc., a UK-based pharmaceutical company, received approval for Calquence (acalabrutinib) from the National Medical Products Administration (NMPA) to market the drug in China for adult patients with mantle cell lymphoma (MCL). Calquence (acalabrutinib) is a selective Bruton's tyrosine kinase (BTK) inhibitor, offering a tolerable and effective new treatment option for controlling mantle cell lymphoma.

Companies operating in the mantle cell lymphoma therapeutics market are innovating by developing products such as kinase inhibitors to broaden their customer bases, increase sales, and boost revenue. A kinase inhibitor is a pharmaceutical agent that interferes with the activity of enzymes called kinases. In January 2023, Eli Lilly and Company, a US-based pharmaceutical company, announced FDA approval for Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets), indicated for adult patients experiencing a recurrence or resistance to prior treatments for mantle cell lymphoma (MCL). Jaypirca, a highly selective kinase inhibitor, utilizes a unique binding mechanism and stands out for its ability to reestablish BTK inhibition in patients with mantle cell lymphoma who have undergone prior treatment with covalent BTK inhibitors.

In August 2022, AstraZeneca plc, a UK-based pharmaceutical and biotechnology company, acquired TeneoTwo Inc. for $1.3 billion. This strategic acquisition aims to diversify and strengthen AstraZeneca's product portfolio by incorporating hematology and mantle cell lymphoma therapeutic drugs. TeneoTwo Inc., a US-based biotechnology company focusing on medicine development for oncology, operates in the mantle cell lymphoma therapeutics market.

Major companies operating in the mantle cell lymphoma therapeutics market report are AstraZeneca plc, Celgene Corporation, Johnson & Johnson Consumer Inc., Takeda Pharmaceutical Company Limited, Bayer Aktiengesellschaft, Eli Lilly and Company, Amgen Inc., GlaxoSmithKline plc, Kite Pharma Inc., Gilead Sciences Inc., AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, Merck & Co. Inc., Massive Bio Inc., Juno Therapeutics Inc., Nurix Therapeutics Inc., Janssen Biotech Inc., TG Therapeutics Inc., F. Hoffmann-La Roche AG, Astex Pharmaceuticals Inc., Astellas Pharma Inc., BeiGene Ltd., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Exelixis Inc., Hutchison China MediTech Limited, Incyte Corporation, Ionis Pharmaceuticals Inc., KalVista Pharmaceuticals Inc.

North America was the largest region in the global mantle cell lymphoma therapeutics market in 2023. The regions covered in the mantle cell lymphoma therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the mantle cell lymphoma therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The mantle cell lymphoma therapeutics market includes revenues earned by entities by brukinsa (zanubrutinib), imbruvica (ibrutinib), Revlimid (lenalidomide), and tecartus (brexucabtagene autoleucel). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Mantle Cell Lymphoma Therapeutics Market Characteristics

3. Mantle Cell Lymphoma Therapeutics Market Trends And Strategies

4. Mantle Cell Lymphoma Therapeutics Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On the Market
  • 4.2. Ukraine-Russia War Impact On the Market
  • 4.3. COVID-19 Impact On the Market

5. Global Mantle Cell Lymphoma Therapeutics Market Size and Growth

  • 5.1. Global Mantle Cell Lymphoma Therapeutics Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Mantle Cell Lymphoma Therapeutics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Mantle Cell Lymphoma Therapeutics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Mantle Cell Lymphoma Therapeutics Market Segmentation

  • 6.1. Global Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Combination Therapy
  • Monotherapy
  • 6.2. Global Mantle Cell Lymphoma Therapeutics Market, Segmentation By Mechanism of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Bruton Tyrosine Kinase Inhibitors
  • Alkylating Agents
  • Deoxyribonucleic Acid Synthesis Inhibitors
  • Microtubule Inhibitors
  • Monoclonal Antibodies
  • Other Mechanisms
  • 6.3. Global Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Parenteral
  • 6.4. Global Mantle Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital
  • Research Institute
  • Other Applications

7. Mantle Cell Lymphoma Therapeutics Market Regional And Country Analysis

  • 7.1. Global Mantle Cell Lymphoma Therapeutics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Mantle Cell Lymphoma Therapeutics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Mantle Cell Lymphoma Therapeutics Market

  • 8.1. Asia-Pacific Mantle Cell Lymphoma Therapeutics Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Mantle Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Mantle Cell Lymphoma Therapeutics Market

  • 9.1. China Mantle Cell Lymphoma Therapeutics Market Overview
  • 9.2. China Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Mantle Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Mantle Cell Lymphoma Therapeutics Market

  • 10.1. India Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Mantle Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Mantle Cell Lymphoma Therapeutics Market

  • 11.1. Japan Mantle Cell Lymphoma Therapeutics Market Overview
  • 11.2. Japan Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Mantle Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Mantle Cell Lymphoma Therapeutics Market

  • 12.1. Australia Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Mantle Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Mantle Cell Lymphoma Therapeutics Market

  • 13.1. Indonesia Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Mantle Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Mantle Cell Lymphoma Therapeutics Market

  • 14.1. South Korea Mantle Cell Lymphoma Therapeutics Market Overview
  • 14.2. South Korea Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Mantle Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Mantle Cell Lymphoma Therapeutics Market

  • 15.1. Western Europe Mantle Cell Lymphoma Therapeutics Market Overview
  • 15.2. Western Europe Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Mantle Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Mantle Cell Lymphoma Therapeutics Market

  • 16.1. UK Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Mantle Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Mantle Cell Lymphoma Therapeutics Market

  • 17.1. Germany Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Mantle Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Mantle Cell Lymphoma Therapeutics Market

  • 18.1. France Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Mantle Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Mantle Cell Lymphoma Therapeutics Market

  • 19.1. Italy Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Mantle Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Mantle Cell Lymphoma Therapeutics Market

  • 20.1. Spain Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Mantle Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Mantle Cell Lymphoma Therapeutics Market

  • 21.1. Eastern Europe Mantle Cell Lymphoma Therapeutics Market Overview
  • 21.2. Eastern Europe Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Mantle Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Mantle Cell Lymphoma Therapeutics Market

  • 22.1. Russia Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Mantle Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Mantle Cell Lymphoma Therapeutics Market

  • 23.1. North America Mantle Cell Lymphoma Therapeutics Market Overview
  • 23.2. North America Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Mantle Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Mantle Cell Lymphoma Therapeutics Market

  • 24.1. USA Mantle Cell Lymphoma Therapeutics Market Overview
  • 24.2. USA Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Mantle Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Mantle Cell Lymphoma Therapeutics Market

  • 25.1. Canada Mantle Cell Lymphoma Therapeutics Market Overview
  • 25.2. Canada Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Mantle Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Mantle Cell Lymphoma Therapeutics Market

  • 26.1. South America Mantle Cell Lymphoma Therapeutics Market Overview
  • 26.2. South America Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Mantle Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Mantle Cell Lymphoma Therapeutics Market

  • 27.1. Brazil Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Mantle Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Mantle Cell Lymphoma Therapeutics Market

  • 28.1. Middle East Mantle Cell Lymphoma Therapeutics Market Overview
  • 28.2. Middle East Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Mantle Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Mantle Cell Lymphoma Therapeutics Market

  • 29.1. Africa Mantle Cell Lymphoma Therapeutics Market Overview
  • 29.2. Africa Mantle Cell Lymphoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Mantle Cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Mantle Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Mantle Cell Lymphoma Therapeutics Market Competitive Landscape And Company Profiles

  • 30.1. Mantle Cell Lymphoma Therapeutics Market Competitive Landscape
  • 30.2. Mantle Cell Lymphoma Therapeutics Market Company Profiles
    • 30.2.1. AstraZeneca plc
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Celgene Corporation
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Johnson & Johnson Consumer Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Takeda Pharmaceutical Company Limited
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Bayer Aktiengesellschaft
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Global Mantle Cell Lymphoma Therapeutics Market Competitive Benchmarking

32. Global Mantle Cell Lymphoma Therapeutics Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Mantle Cell Lymphoma Therapeutics Market

34. Mantle Cell Lymphoma Therapeutics Market Future Outlook and Potential Analysis

  • 34.1 Mantle Cell Lymphoma Therapeutics Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 Mantle Cell Lymphoma Therapeutics Market In 2028 - Segments Offering Most New Opportunities
  • 34.3 Mantle Cell Lymphoma Therapeutics Market In 2028 - Growth Strategies
    • 34.3.1 Market Trend Based Strategies
    • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35.4. Research Inquiries
  • 35.5. The Business Research Company
  • 35.6. Copyright And Disclaimer